Introduction
TABLE OF CONTENTS
6 TO 50
383 TO 406
This caption mainly comprises long-term investments with the Group's cash pool.
Cash and cash equivalents can be broken down as follows:
| € millions | 31.12.2024 | 31.12.2023 | 31.12.2022 |
|---|---|---|---|
| Cash and cash equivalents |
Cash and cash equivalents 31.12.2024 290.7 |
Cash and cash equivalents 31.12.2023 337.7 |
Cash and cash equivalents 31.12.2022 616.2 |
| Accrued interest receivable |
Accrued interest receivable 31.12.2024
|
Accrued interest receivable 31.12.2023 9.4 |
Accrued interest receivable 31.12.2022 1.8 |
| Accrued interest payable |
Accrued interest payable 31.12.2024
|
Accrued interest payable 31.12.2023 — |
Accrued interest payable 31.12.2022 — |
| NET CASH AND CASH EQUIVALENTS |
NET CASH AND CASH EQUIVALENTS 31.12.2024 290.7 |
NET CASH AND CASH EQUIVALENTS 31.12.2023 347.1 |
NET CASH AND CASH EQUIVALENTS 31.12.2022 618.0 |
Statutory audit fees are presented in note 16 to the consolidated financial statements.
Signing of an agreement for the sale of 2.3% of Sanofi shares
The L'Oréal Groupe announced on 3 February 2025 the signing of an agreement for the sale of approximately 29.6 million Sanofi shares to Sanofi at a price of €101.5 per share, i.e., a total consideration of €3 billion. Following completion of the transaction and cancellation of the shares bought back, L'Oréal will hold 7.2% of Sanofi's share capital and 13.1% of the voting rights(1).
The transaction, which will be carried out through an off-market block trade, is not subject to any condition precedent and should be finalized in the coming days.
DETAILED INFORMATION
| Share capital | Reserves and retained earnings before appropriation of net profit | % interest | Carrying amount of shares held | Profit or loss in last financial year | Dividends(1) booked during the financial year | ||
|---|---|---|---|---|---|---|---|
| Gross | Net | ||||||
| A. Main French subsidiaries (more than 50% interest) | |||||||
| Azzaro Mugler Beauté France | 78,723 | 945 | 100.00% | 78,723 | 78,723 | 1,128 | 906 |
| Beauté, Recherche & Industries | 1,069 | 15,059 | 100.00% | 9,495 | 9,495 | 9,298 | 3,802 |
| Cosmétique Active International | 19 | 13,947 | 88.97% | 15,100 | 15,100 | 149,596 | 112,553 |
| Cosmétique Active Production | 186 | 24,834 | 80.13% | 5,081 | 5,081 | 19,478 | 11,021 |
| EpiSkin | 13,609 | 13,060 | 99.92% | 17,999 | 17,999 | (169) | — |
| Fapagau & Cie | 15 | 6,201 | 79.00% | 12 | 12 | 20,653 | 11,009 |
| Faproreal | 11,944 | 5,430 | 100.00% | 11,953 | 11,953 | 5,823 | 6,382 |
| Finval | 19,516 | 142,683 | 100.00% | 75,677 | 75,677 | 74,410 | 40,258 |
| Gemey Paris – Maybelline New York | 35 | 8,532 | 99.96% | 46 | 46 | 5,102 | 5,581 |
| Holdial | 1 | 1 | 98.00% | 1 | 1 | 1,192 | 1,225 |
(1) Based on a total number of 1,263,122,721 shares outstanding and 1,413,130,110 voting rights at 31 December 2024, as published by Sanofi, it being specified that the percentage of theoretical voting rights held by L'Oreal after cancellation will be 13.0% based on the total number of 1,422,661,191 theoretical voting rights as at 31 December 2024, as published by Sanofi, in each case adjusted for the number of shares bought back and cancelled following or as a result of the transaction. Before cancellation of the shares bought back, L'Oreal interest in Sanofi will represent 7.0% of the share capital and 12.7% of the total number of theoretical voting rights.